Diabetic Foot Ulcer Treatment

Diabetic patients, especially in Epidermal Growth Factor receptor (EGF), generally have a decreased amount of growth factor concentrations. EGF is an important growth factor that promotes cell growth and cell proliferation by binding to Epidermal Growth Factor (EGFR) receptors. A reduced amount of EGF affects the healing of wounds leading to such extremes that may require amputation.

The Center for Genetic Engineering and Biotechnology (CIGB) of Cuba has developed the drug Heberprot-P for the treatment of severe diabetic foot ulcer. Heberprot-P contains Epidermal Growth Factor (EGF) as its main ingredient and is parenterally administered (Intra-lesional injections directly into the wound), encouraging the progress and sustained healing of the lesions. Approximately 160,000 patients with diabetic foot ulcer have been treated with Heberprot-P with success reducing the risk of amputation by %75.

Heberprot-P is administered for the treatment of patients suffering from chronic non-healing wounds with poor prognosis and those who do not respond to extensive conventional treatment methods.